Inhibiting VEGF-C/VEGFR-3 signaling suppresses tumor lymphangiogenesis and lymphatic metastasis in pre-clinical models and may be a promising strategy for treating ESCC and other cancers [10-13]. The gene discussed is VEGFC; the disease is neoplasm.